Investors Still Must Pick Generic Drug Companies By Hand

The high-risk generic drug sector still is without an ETF, leaving investors to weed out the pharmaceutical winners and losers for themselves. More 

Apple Bombs, Sectors Revolt — Tuesday’s IP Market Recap

Apple records a rare earnings miss after the bell, and Goldman Sachs and IBM misses couldn't hold back financials and techs Tuesday. More 

7 Pharma Stocks to Sell, STAT

Pharmaceutical stocks are theoretically recession-proof. Still, not all pharma companies are equal. Here are seven clear losers to toss. More 

Shortage of Cancer Drugs Jeopardizes Development of New Treatments

Existing products often are used in new drugs' clinical trials, meaning a cramp in supply can result in delays of even years for new treatments. More 

New CEO Tasked with Getting Hospira Back on Track

Priorities for Hospira's new CEO include fixing manufacturing problems, launching biosimilars in the U.S. More